- Home
- VICR vs DNLI Comparison
VICR vs DNLI Comparison
Compare VICR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VICR
- DNLI
- Stock Information
- Founded
- VICR 1981
- DNLI 2013
- Country
- VICR United States
- DNLI United States
- Employees
- VICR N/A
- DNLI N/A
- Industry
- VICR Industrial Machinery/Components
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VICR Technology
- DNLI Health Care
- Exchange
- VICR Nasdaq
- DNLI Nasdaq
- Market Cap
- VICR 2.3B
- DNLI 2.1B
- IPO Year
- VICR N/A
- DNLI 2017
- Fundamental
- Price
- VICR $48.63
- DNLI $14.99
- Analyst Decision
- VICR Hold
- DNLI Strong Buy
- Analyst Count
- VICR 2
- DNLI 15
- Target Price
- VICR $43.00
- DNLI $33.50
- AVG Volume (30 Days)
- VICR 278.1K
- DNLI 2.1M
- Earning Date
- VICR 10-21-2025
- DNLI 11-05-2025
- Dividend Yield
- VICR N/A
- DNLI N/A
- EPS Growth
- VICR 576.06
- DNLI N/A
- EPS
- VICR 1.45
- DNLI N/A
- Revenue
- VICR $379,346,000.00
- DNLI N/A
- Revenue This Year
- VICR $20.25
- DNLI N/A
- Revenue Next Year
- VICR $4.82
- DNLI $95,463.19
- P/E Ratio
- VICR $33.54
- DNLI N/A
- Revenue Growth
- VICR 2.46
- DNLI N/A
- 52 Week Low
- VICR $38.93
- DNLI $10.57
- 52 Week High
- VICR $65.70
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- VICR 44.24
- DNLI 57.22
- Support Level
- VICR $48.60
- DNLI $12.58
- Resistance Level
- VICR $50.17
- DNLI $15.75
- Average True Range (ATR)
- VICR 1.87
- DNLI 0.65
- MACD
- VICR -0.49
- DNLI 0.21
- Stochastic Oscillator
- VICR 14.03
- DNLI 76.97
About VICR Vicor Corporation
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.